The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
Official Title: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Study ID: NCT05018273
Brief Summary: A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The Regents of the University of California, San Francisco, California, United States
Yale Cancer Institute, New Haven, Connecticut, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Washington University, Saint Louis, Missouri, United States
MD Andersson, Houston, Texas, United States
Charité-Universitätsmedizin Berlin, Berlin, , Germany
Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, , Germany
Hospital Universitario Virgen de la Victoria, Campus Universitario De Teatinos s/n, Málaga, MA, Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, , Spain
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
Hospital General Universitario Gregorio Marañón, Madrid, , Spain
Hospital Universitario La Paz, Madrid, , Spain